{"filings":[{"id":2226639,"accession_number":"0001493152-26-037592","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-08-13T12:15:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.","Cash and equivalents $2.2M plus $0.7M restricted; going concern assumption within one year.","Merger with Eos SENOLYTIX expected to close Q3 2026; Form S-4 filed July 9, amended Aug 3.","G&A expenses down to $1.0M from $1.5M; all clinical development on hold to license/monetize assets.","iSPERSE patent portfolio ~142 granted patents, 17 US; PUR1900 Phase 3 in India by Cipla."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452876,"accession_number":"0001493152-26-023367","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-05-15T12:20:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.","Cash and equivalents $3.3M at March 31, 2026; going concern assumed through anticipated merger close.","Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026; common stock holders get ~6% of combined co.","Private placement of Series B convertible preferred stock from Eos affiliate raised $1.0M gross in March.","R&D expense <$0.1M; G&A down to $1.3M from $1.8M; clinical programs on hold pending out-license."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93782,"accession_number":"0001493152-26-018202","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix closes $1M Series B preferred placement as part of planned merger with Eos","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gross proceeds of approximately $1 million from Series B Preferred Stock issued to Eos affiliate.","Conversion price of $2.20 per share; convertible 90 days after issuance.","Placement is an initial step in the planned merger with Eos SENOLYTIX; definitive agreement signed.","Net proceeds to be used for working capital and general corporate purposes.","Interim CEO Peter Ludlum highlighted the investment as part of the ongoing merger process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105690,"accession_number":"0001493152-26-013266","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","3.02","3.03","5.01","5.03","7.01","9.01"],"status":"ready","headline":"Pulmatrix to merge with Eos SENOLYTIX; Eos stockholders to own ~94% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-Merger Eos stockholders to own ~94% of combined company; Pulmatrix stockholders ~6% on fully-diluted basis.","Combined company to be renamed 'Eos SENOLYTIX, Inc.'; board of 6 members, 5 designated by Eos.","Pulmatrix raises $1M via Series B Convertible Preferred (8% dividend, conversion at $2.20) from Eos affiliate.","Eos to raise up to $18M via convertible notes (8% interest) and Series A Preferred financing.","Closing conditions include stockholder approvals, Nasdaq listing, and SEC registration statement effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105689,"accession_number":"0001493152-26-008449","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix merger with Cullgen terminated; seeks alternative merger opportunities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cullgen terminated the Merger Agreement on Feb 28, 2026 citing failure to obtain China Securities Regulatory Commission approval.","No termination fee payable by either party; each will bear its own costs and expenses.","Pulmatrix continues pursuing alternative reverse merger opportunities, encouraged by industry activity.","Prior mutual waiver of no-solicitation clause had already allowed each party to explore alternate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105688,"accession_number":"0001493152-26-008129","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.","Cash and equivalents $4.1M at Dec 31, 2025, down from $9.5M; cash runway into Q1 2027.","Plans to license or monetize iSPERSE platform and migraine asset PUR3100.","Proposed merger with Cullgen pending CSRC approval; 'No Solicitation' clause waived to explore alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121970,"accession_number":"0001493152-25-028283","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix and Cullgen waive no-solicitation clause, explore alternatives due to CSRC delay","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Parties mutually waived the 'No Solicitation' clause (Section 5.4) of the Nov 2024 Merger Agreement.","Waiver permits each party to explore alternate transactions while continuing to pursue CSRC merger approval.","CSRC approval remains the primary unmet closing condition; S-4 effective May 2025, stockholder vote June 2025.","Pulmatrix had $4.8M cash as of Sept 30, 2025, funding operations into at least Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121969,"accession_number":"0001493152-25-018252","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.","Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.","Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.","R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.","PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138670,"accession_number":"0001641172-25-022354","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports Q2 2025 net loss $1.5M; merger with Cullgen expected 2025; plans divestment of iSPERSE assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $0 from $1.6M in Q2 2024 due to PUR1900 wind-down; net loss $1.549M ($0.42 per share).","Cash and equivalents $5.825M; company expects funds to last through expected close of proposed Cullgen merger.","Proposed merger with Cullgen approved by stockholders; closing in 2025 subject to Nasdaq and China regulatory approvals.","Pulmatrix intends to divest iSPERSE technology and clinical programs PUR3100, PUR1800, PUR1900 as part of merger.","R&D expenses dropped to $0.1M from $2.8M; G&A decreased to $1.5M from $2.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156123,"accession_number":"0001641172-25-015249","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Pulmatrix stockholders approve merger proposals; CSRC clearance still outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven proposals approved by stockholders at June 16 special meeting, including issuance of shares for Cullgen merger.","Reverse stock split authorized at ratio of 1-for-2 to 1-for-10, with final ratio to be set by board; authorized shares increased to 250M.","Merger remains subject to CSRC approval under China's Trial Measures; Pulmatrix notes CSRC approval not yet received.","Richard Batycky re-elected as Class II director; CBIZ CPAs ratified as auditor for FY2025 (subject to change post-merger).","Proposal 1 (share issuance >20% and change of control) passed with 798,652 votes for, 65,788 against, 2,428 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156122,"accession_number":"0001641172-25-010525","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.","Cash balance $7.7M; expects to fund operations through merger close in June 2025.","Merger with Cullgen anticipated to close in June 2025; registration declared effective by SEC.","Company intends to divest assets including PUR3100 (Phase 2-ready acute migraine candidate) and iSPERSE technology.","R&D expenses decreased to less than $0.1M from $3.5M YoY due to wind-down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156121,"accession_number":"0001641172-25-003620","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["1.01","5.01","9.01"],"status":"ready","headline":"Pulmatrix and Cullgen amend merger agreement to one-step merger; Second Merger Sub removed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 1 dated April 7, 2025 changes transaction from two-step to one-step merger, eliminating Second Merger Sub.","Clarifies fractional shares provision; Cullgen will survive as wholly owned subsidiary of Pulmatrix.","Boards of both companies approved the amendment; all other terms of original November 13, 2024 agreement remain.","Transaction remains subject to stockholder approval, regulatory clearances, and Nasdaq listing; consideration unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156120,"accession_number":"0001641172-25-003216","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Pulmatrix auditor change: Marcum resigns, CBIZ engaged effective April 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 4, 2025; no adverse opinions or disagreements in prior reports.","Audit Committee approved engagement of CBIZ CPAs P.C. as new independent auditor for fiscal 2025.","Auditor transition follows CBIZ’s November 2024 acquisition of Marcum’s attest business.","No reportable events or disagreements occurred during 2023, 2024, or interim period through April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174557,"accession_number":"0001493152-25-011082","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.","Revenues increased to $7.8M from $7.3M, driven by a contract modification with Cipla.","Cash and equivalents $9.5M; sufficient to fund operations through anticipated Merger close in H1 2025.","Proposed merger with Cullgen expected to close H1 2025; plans to divest Phase 2-ready PUR3100 and iSPERSE technology.","PUR1900 Phase 2b enrollment paused; no further financial responsibility; 2% royalties on future net sales outside U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174556,"accession_number":"0001493152-25-006588","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pulmatrix amends bylaws to revise voting standards language","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board approved Amendment No. 2 on Feb 11, 2025, effective immediately.","Amendment revises voting standards language in Article I, Section 7 of the Bylaws.","No specific details on the change were disclosed; routine governance update.","No financial or operational impact stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191519,"accession_number":"0001493152-24-050889","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmatrix stockholders elect two Class I directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Todd Bazemore and Christopher Cabell as Class I directors with votes for 285,646 and 334,230, respectively.","Ratified Marcum LLP as independent auditor for FY2024: 1,705,315 for, 47,547 against, 103,282 abstain.","Annual meeting quorum: 1,856,171 shares (50.82% outstanding); broker non-votes on director elections: 1,318,725.","No other proposals were considered or voted upon at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191518,"accession_number":"0001493152-24-044986","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix to merge with Cullgen in reverse merger; Cullgen holders to own 96.4%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pulmatrix to merge with Cullgen; exchange ratio implies Cullgen valuation of $280M, Pulmatrix $10.5M.","Pre-merger Cullgen stockholders to own ~96.4% of combined company; Pulmatrix stockholders ~3.6%.","Pulmatrix plans cash dividend to pre-merger stockholders if net cash exceeds $2.5M at closing.","Combined company board: eight members, seven from Cullgen, one from Pulmatrix.","Closing conditions include stockholder votes, Nasdaq listing, SEC S-4 effectiveness, CSRC approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191517,"accession_number":"0001493152-24-044160","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.","Revenue fell to $0.4M from $1.8M due to PUR1900 wind down; R&D expenses cut 80% to $0.8M.","Cash and equivalents $10.8M; company expects funding into Q4 2026.","Completed wind down of PUR1900 Phase 2b; no further financial obligation, to receive 2% royalties ex-US.","Closed MannKind cross-license for iSPERSE technology; pursuing strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7803000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191516,"accession_number":"0001493152-24-040453","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Pulmatrix sets 2024 annual meeting for Dec 18; Oct 31 record date","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting scheduled for Wednesday, December 18, 2024.","Record date for stockholders entitled to vote is October 31, 2024.","Stockholder proposals for proxy inclusion due by October 18, 2024, under Rule 14a-8.","Deadline for other business nominations and universal proxy rule compliance is also October 18, 2024.","Meeting date changed by more than 30 days from 2023 annual meeting anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207998,"accession_number":"0001493152-24-031477","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.","Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.","Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.","Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":7437000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207997,"accession_number":"0001493152-24-028507","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Teofilo Raad departs Pulmatrix; Peter Ludlum appointed Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Teofilo Raad separated as CEO and Board member effective July 19, 2024; severance includes $567,294 salary, $156,310 prorated bonus, $283,647 separation bonus.","Peter Ludlum appointed Interim CEO effective July 20, 2024; also continues as Interim CFO; compensated at $700/hour via Danforth Advisors.","Ludlum eligible for retention bonuses totaling $50,000 ($30,000 upfront, $20,000 after annual meeting).","Raad's departure is not due to any disagreement regarding company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225526,"accession_number":"0001493152-24-021732","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.","MannKind grants Pulmatrix exclusive Cricket device license for PUR3100 (DHE/migraine); non-exclusive for neurological disease.","MannKind assumes Pulmatrix's Bedford R&D facility lease and equipment; expected close July 2024.","CEO: transaction validates iSPERSE technology and extends cash runway into 2026.","MannKind to provide development services under MSA and may hire some Pulmatrix R&D staff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225525,"accession_number":"0001493152-24-019558","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.","Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.","Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.","Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225524,"accession_number":"0001493152-24-018576","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.","Net income $0.8M vs net loss $4.4M in prior year.","Cash $16.3M; expects cash runway into Q1 2026.","PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.","PUR3100 Phase 2-ready; seeking partnership for Phase 2 study."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":5885000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244692,"accession_number":"0001493152-24-011627","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports FY2023 net loss narrowed; cash runway extended to Q1 2026 on Cipla amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $19.2M at Dec 31, 2023; projected runway into Q1 2026.","Net loss $14.1M ($3.87/share) for FY2023, improved from $18.8M ($5.46/share) in FY2022.","Revenue $7.3M, up $1.2M YoY due to higher PUR1900 activity under Cipla agreement.","Cipla amendment: wind-down of PUR1900 Phase 2b; Pulmatrix gets 2% royalty on net sales, no further development cost.","R&D spend fell $2.7M to $15.5M; G&A fell $0.3M to $6.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244691,"accession_number":"0001493152-24-009751","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pulmatrix terminates CMO Dr. Margaret Wasilewski; transitions to outsourced part-time CMO model","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated CMO Dr. Margaret Wasilewski on March 7, 2024; position eliminated for transition to outsourced part-time CMO model.","Termination not due to any disagreement regarding operations, policies, or practices.","Severance, unpaid bonus, and health insurance premiums to be paid per employment letter dated January 27, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244690,"accession_number":"0001493152-24-008705","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix furnishes corporate presentation for March 2024; content not provided in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 as a Regulation FD disclosure of a slide presentation dated March 2024.","No specific financial or pipeline details are available from the filing text or exhibit summary.","Presentation intended for investor and industry conferences; company has no obligation to update.","Confidence in material facts is low because the exhibit text was not included in the input."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244689,"accession_number":"0001493152-24-001667","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix halts PUR1900 Ph2b study; Cipla assumes ex-US development for 2% royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment stopped at 8 subjects; study wind-down expected by July 2024; Pulmatrix's cash burn significantly reduced.","Cipla gets exclusive rights to all markets outside the US; Pulmatrix receives 2% royalty on net sales in Cipla Territory.","Cash on hand ~$19M as of Dec 31, 2023; cash runway extended into Q1 2026.","CEO Teofilo Raad granted retention bonus of $170K/quarter for Q1 and Q2 2024, payable on employment conditions.","Company retained MTS Health Partners to review strategic alternatives to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262119,"accession_number":"0001493152-23-040009","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.","Cash $21.3M, down from $35.6M at Dec 2022; projected runway into Q1 2025.","PUR1900 Phase 2b in ABPA ongoing; topline data expected H2 2024.","PUR3100 IND cleared for Phase 2 in acute migraine; study start contingent on financing.","PUR1800 Phase 1b completed; seeking partnership for Phase 2."],"consensus_eps_estimate":-1.071,"consensus_eps_actual":-3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":5096000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279335,"accession_number":"0001493152-23-027464","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q2 2023: cash $25.8M, net loss $3.8M; PUR1900 Phase 2b enrollment ongoing, topline Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $25.8M as of June 30, 2023; projected runway into Q1 2025.","Q2 revenue $1.8M (up from $1.3M YoY); net loss $3.8M ($1.04 per share).","PUR1900 Phase 2b for ABPA enrolling; 13 sites active; topline data expected Q3 2024.","IND filed for PUR3100 Phase 2 in acute migraine; partnership needed to start trial.","Phase 1b data for PUR1800 in AECOPD presented; partnership opportunities being pursued."],"consensus_eps_estimate":-1.0608,"consensus_eps_actual":-2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":3343000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279334,"accession_number":"0001493152-23-024462","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmatrix shareholders elect directors, ratify auditor; say-on-pay passes narrowly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Michael J. Higgins (758,720 for, 533,500 withheld) and Anand Varadan (1,014,129 for, 278,091 withheld) as Class III directors until 2026.","Ratified Marcum LLP as independent auditor for FY2023 with 1,860,275 for, 251,489 against, 70,155 abstain.","Advisory say-on-pay vote passed with 603,083 for (51.6% of votes cast), 565,062 against, 124,075 abstain, 889,699 broker non-votes.","Quorum was 59.74% (2,181,919 shares) as of May 24, 2023 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279333,"accession_number":"0001493152-23-024176","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.","Phase 1 data showed PK similar to IV DHE with fewer side effects.","Phase 2 protocol investigates safety and preliminary efficacy in migraine patients.","Approximately 40 million U.S. patients with acute migraine need additional options.","PUR3100 uses proprietary iSPERSE dry powder delivery technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297701,"accession_number":"0001493152-23-016511","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports Q1 net loss $4.45M; cash runway extended to Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.45M ($1.22 per share) vs $4.97M loss in Q1 2022.","Revenue $1.5M, up from $1.2M, mainly from Cipla agreement.","Cash $30.8M; projected runway extended from Q2 2024 to Q4 2024.","Phase 2b PUR1900 trial dosing initiated for ABPA; topline data expected mid-2024.","Phase 1 PUR3100 migraine study positive; IND filing planned mid-2023, Phase 2 pending financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1499000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317976,"accession_number":"0001493152-23-009607","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports FY2022 revenue $6.1M, net loss $18.8M; cash $35.6M into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.1M (+$0.9M YoY); net loss $18.8M vs $20.2M; EPS -$5.46 vs -$8.63.","Cash $35.6M at Dec 31, 2022; runway into Q2 2024.","PUR1900 Phase 2b in ABPA dosed first patients in Q1 2023; topline data expected mid-2024.","PUR3100 Phase 1 for acute migraine positive: lower nausea vs IV DHE; plans for Phase 2.","PUR1800 Phase 1b data presented; analysis ongoing for potential Phase 2 study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317975,"accession_number":"0001493152-23-003649","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.","Study targets 30 subjects across US, UK, Australia, France; 3 arms: placebo, 20 mg, 40 mg daily for 16 weeks plus 8-week follow-up.","Partnership with Cipla; proof-of-concept data expected by mid-2024.","PUR1900 aims to be first approved ABPA treatment, reducing systemic side effects of oral antifungals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317974,"accession_number":"0001493152-23-003480","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix 8-K attaches slide deck for KOL event; no material facts disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing provides no specific financial, clinical, or operational data; slide content not included in excerpt.","Slide presentation presented at virtual Key Opinion Leader Event on February 3, 2023, per Item 7.01.","No new guidance, results, or business updates can be derived from the limited filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317973,"accession_number":"0001493152-23-002394","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix to host KOL webinar on PUR3100 for acute migraine on Feb 3, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webinar on Feb 3, 2023 at 10:00 AM ET, featuring Prof. Stewart Tepper (Dartmouth).","Dr. Margaret Wasilewski to provide update on Phase 1 data for inhaled DHE candidate PUR3100.","Event aims to discuss migraine treatment landscape, DHE mechanism, and future clinical plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317972,"accession_number":"0001493152-23-001159","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix furnishes January 2023 investor presentation; no material details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["The filing includes a slide presentation for use at investor conferences, but the presentation content is not provided in the extracted text.","No financial results, guidance, or operational updates are disclosed in the 8-K or available exhibit.","Company states it may update the presentation from time to time but undertakes no obligation to do so.","The information is furnished under Regulation FD and not deemed filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317971,"accession_number":"0001493152-23-000232","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix reports positive Phase 1 results for inhaled migraine drug PUR3100; Tmax 5 min, fewer GI side effects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.","Peak plasma concentration (Cmax) reached targeted therapeutic range at all three doses; Tmax of 5 minutes.","Phase 2 dose selection underway; FDA meeting requested in January 2023.","Study enrolled 26 healthy subjects in double-dummy, double-blinded design comparing inhaled PUR3100 vs IV DHE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336235,"accession_number":"0001493152-22-031516","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.","Cash and equivalents $40.7M; expects to fund ops into Q2 2024; raised $1.4M via ATM at ~$5.70/share.","PUR1900 Phase 2 study for ABPA to start dosing in Q1 2023; 16-week regimen.","PUR3100 Phase 1 data for acute migraine anticipated early Q1 2023; database lock in November.","PUR1800 Phase 1b data analysis ongoing for presentation at 2023 medical conference."],"consensus_eps_estimate":-1.071,"consensus_eps_actual":-4.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":4363000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353651,"accession_number":"0001493152-22-026760","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix completes dosing in Phase 1 trial of inhaled PUR3100 for acute migraine; data expected Q4 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.","Phase 1 safety, tolerability, and PK data expected in Q4 2022.","PUR3100 uses iSPERSE dry-powder technology for self-administered inhaled delivery of dihydroergotamine.","Migraine affects 38M in U.S.; 75% do not get relief from current prescription treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353650,"accession_number":"0001493152-22-021835","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q2 revenue falls 41% to $1.3M; net loss widens to $4.6M; cash $42.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 revenue $1.3M vs $2.2M in Q2 2021; decrease driven by no PUR1800 revenue offset by Cipla agreement for Pulmazole.","Net loss of $4.6M ($1.36 per share) vs $3.9M ($1.37) in Q2 2021; wider loss on lower revenue.","Cash and equivalents $42.9M at June 30, 2022; expects to fund operations into Q2 2024.","PUR3100 Phase 1 study dosed 23 of 24 patients; top-line data expected Q4 2022.","Pulmazole Phase 2b study start-up initiated; patient dosing on track for Q1 2023."],"consensus_eps_estimate":-1.0608,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":2491000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353649,"accession_number":"0001493152-22-019049","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.","Phase 1 is a double-dummy, double-blinded trial assessing safety, tolerability, and PK of 3 inhaled doses vs IV DHE in 24 healthy volunteers.","Data including safety, tolerability, and pharmacokinetics expected in Q4 2022 to guide dose selection for registration-enabling studies.","Dr. Margaret Wasilewski, CMO, cited oral inhalation as potentially more convenient than IV or nasal DHE with fewer side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371426,"accession_number":"0001493152-22-016861","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmatrix reports annual meeting vote results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["1,490,945 shares (44.02% of outstanding) present, constituting a quorum.","Teofilo Raad elected as Class II director with 422,137 votes for, 178,197 against.","Richard Batycky elected as Class II director with 448,559 votes for, 151,775 against.","Ratification of Marcum LLP as auditor for 2022: 1,378,659 for, 97,469 against, 14,817 abstain.","All director nominees and auditor proposal passed with majority support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371425,"accession_number":"0001493152-22-012938","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.","Ended Q1 with $47.5M cash; cash runway extended into Q2 2024, through Pulmazole Phase 2b data readout.","Pulmazole Phase 2b on track to start dosing Q1 2023; top-line data expected Q2 2024.","PUR3100 Phase 1 top-line data expected in Q4 2022 from Australian study.","Completed 1-for-20 reverse stock split and regained Nasdaq compliance in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1160000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371424,"accession_number":"0001493152-22-011543","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pulmatrix reduces stockholder quorum requirement from majority to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved bylaw amendment lowering quorum to one-third of voting power.","Effective immediately as of April 28, 2022.","Amendment restates Article I, Section 4 of the existing bylaws.","Quorum reduced from majority to one-third for all stockholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371423,"accession_number":"0001493152-22-010083","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pulmatrix appoints Peter Ludlum as Interim CFO effective April 18, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Ludlum appointed Interim CFO, Principal Accounting Officer, and Principal Financial Officer effective April 18, 2022.","Ludlum is a Danforth Advisors employee; services provided under consulting agreement at $400/hour.","Ludlum has 17 years C-level finance experience, previously CFO at Emmaus Life Sciences.","No family relationships or reportable transactions with Pulmatrix.","Appointment fills vacancy until a successor is chosen or earlier resignation/removal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390389,"accession_number":"0001493152-22-007956","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).","Cash $53.8M at Dec 31, 2021; raised $46.75M in 2021; funded into Q1 2024.","Hired Dr. Margaret Wasilewski as CMO; completed 1-for-20 reverse stock split; regained Nasdaq compliance.","Pulmazole Phase 2b in ABPA to start Q1 2023, data mid-2024; PUR3100 Phase 1 in Australia Q3 2022.","PUR1800 Phase 1b met safety endpoint; preclinical tox supports chronic dosing in COPD, asthma, IPF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390388,"accession_number":"0001493152-22-007328","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.","Preliminary PK shows low and consistent systemic exposure via oral inhalation.","Company expects to advance PUR1800 to Phase 2 studies for AECOPD.","Results to be submitted at a medical conference later in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390387,"accession_number":"0001493152-22-007156","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulmatrix regains compliance with Nasdaq minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 15, 2022 that minimum bid price compliance is regained.","Previously notified of non-compliance on August 17, 2021 for failing to maintain $1.00 bid price.","Regained compliance by closing at $1.00 or more for at least 10 consecutive trading days through March 14, 2022.","Nasdaq has closed the compliance matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-17T23:59:59+00:00|390387"}